Grant List
Represents Grant table in the DB
GET /v1/grants?page%5Bnumber%5D=1382&sort=title
{ "links": { "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=title", "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1397&sort=title", "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1383&sort=title", "prev": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1381&sort=title" }, "data": [ { "type": "Grant", "id": "8564", "attributes": { "award_id": "1R21AI161104-01", "title": "VPS34 inhibitors as SARS-CoV-2 antivirals", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 6011, "first_name": "Erik J.", "last_name": "Stemmy", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2021-08-01", "end_date": "2021-11-15", "award_amount": 13111, "principal_investigator": { "id": 8360, "first_name": "Christopher F", "last_name": "Basler", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 625, "ror": "https://ror.org/04a9tmd77", "name": "Icahn School of Medicine at Mount Sinai", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 964, "ror": "https://ror.org/03qt6ba18", "name": "Georgia State University", "address": "", "city": "", "state": "GA", "zip": "", "country": "United States", "approved": true }, "abstract": "SARS-CoV-2, a Betacoronavirus genus, is an enveloped positive-sense, RNA virus responsible for a current pandemic. Because of its profound impact on society and human health there is an urgent need to understand SARS-CoV-2 replication requirements and to identify therapeutic strategies. Repurposing drugs developed for other purposes may provide a shortcut to therapeutic development. The use of compounds known to target specific host factors may also elucidate key pathways needed for virus replication. Coronavirus (CoV) replication involves multiple critical interactions with host cell membranes. One of the most striking features of CoV infection is the establishment of membrane-associated replication organelles that serve as the main sites of viral RNA synthesis. The origin of these membrane organelles is incompletely understood. Because the specific host pathways required for SARS-CoV-2 replication organelle formation are not defined, we asked whether SARS-CoV-2 is susceptible to modulators of lipid metabolism by assessing the sensitivity of the virus to VPS34 inhibitors of VPS34, a lipid kinase required for autophagy and endosomal trafficking; Triacsin C, an inhibitor of long chain fatty acyl CoA synthetase (ACSL) and Orlistat, an inhibitor of fatty acid synthase (FASN). Our preliminary data indicate that inhibitors of VPS34 potently inhibited SARS-CoV-2 replication, whereas an FDA- approved inhibitor of a different class of PI3K had minimal effect on replication. Targeting FASN and ACSL also impairs SARS-CoV-2 replication. These data suggest that VPS34, ACSL and FASN play important roles in replication center formation and virus growth and suggest these enzymes as therapeutic targets. We will test the hypothesis that VPS34, ACSL and FASN are critical for SARS-Cov-2 infection by evaluating additional small molecule inhibitors of these enzymes and by measuring SARS-CoV-2 replication in genetic knockdowns or knockouts of these host enzymes. We will define mechanisms of inhibition and test the hypothesis that generation of membrane-associated viral replication centers will be disrupted. Finally, we will assess the in vivo efficacy of VSP34 inhibitor PIK-III and systemically administered Orlistat in SARS-coV-2- infected hamsters to evaluate the therapeutic potential of inhibitors of lipid metabolism.", "keywords": [ "1-Phosphatidylinositol 3-Kinase", "2019-nCoV", "Acyl Coenzyme A", "Address", "Antiviral Agents", "Autophagocytosis", "Biological Assay", "COVID-19", "COVID-19 patient", "COVID-19 treatment", "Cell membrane", "Cells", "Clinical", "Coenzyme A Ligases", "Coronavirus", "Coronavirus Infections", "Data", "Development", "Diabetes Mellitus", "Endoplasmic Reticulum Degradation Pathway", "Enzyme Inhibitor Drugs", "Enzymes", "Exhibits", "FDA approved", "Fatty-acid synthase", "Generations", "Genetic", "Growth", "Hamsters", "Health", "Human", "Impairment", "Infection", "Integration Host Factors", "Knock-out", "Lipids", "Malignant Neoplasms", "Measures", "Medical", "Membrane", "Membrane Biology", "Mesocricetus auratus", "Metabolic", "Microscopy", "Modeling", "Natural Immunity", "Nonstructural Protein", "Obesity", "Oral", "Organelles", "Outcome", "Palmitates", "Pathway interactions", "Pharmacology", "Phosphotransferases", "Play", "Proteins", "Proteomics", "RNA Viruses", "RNA chemical synthesis", "Regulation", "Replicon", "Role", "SARS-CoV-2 infection", "Site", "Societies", "Testing", "Therapeutic", "Therapeutic Intervention", "Time", "Vesicle", "Viral", "Virus", "Virus Replication", "base", "betacoronavirus", "cytotoxicity", "drug repurposing", "in vivo", "inhibitor/antagonist", "innovation", "insight", "interest", "knock-down", "lipid metabolism", "lipid transport", "long chain fatty acid", "member", "novel", "orlistat", "pandemic disease", "phosphatidylinositol 3-phosphate", "remdesivir", "small molecule", "small molecule inhibitor", "targeted treatment", "therapeutic development", "therapeutic target", "trafficking", "transcriptomics", "triacsin C", "viral RNA" ], "approved": true } }, { "type": "Grant", "id": "8565", "attributes": { "award_id": "7R21AI161104-02", "title": "VPS34 inhibitors as SARS-CoV-2 antivirals", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 6011, "first_name": "Erik J.", "last_name": "Stemmy", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2021-08-01", "end_date": "2023-07-31", "award_amount": 415889, "principal_investigator": { "id": 8360, "first_name": "Christopher F", "last_name": "Basler", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 625, "ror": "https://ror.org/04a9tmd77", "name": "Icahn School of Medicine at Mount Sinai", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 625, "ror": "https://ror.org/04a9tmd77", "name": "Icahn School of Medicine at Mount Sinai", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true }, "abstract": "SARS-CoV-2, a Betacoronavirus genus, is an enveloped positive-sense, RNA virus responsible for a current pandemic. Because of its profound impact on society and human health there is an urgent need to understand SARS-CoV-2 replication requirements and to identify therapeutic strategies. Repurposing drugs developed for other purposes may provide a shortcut to therapeutic development. The use of compounds known to target specific host factors may also elucidate key pathways needed for virus replication. Coronavirus (CoV) replication involves multiple critical interactions with host cell membranes. One of the most striking features of CoV infection is the establishment of membrane-associated replication organelles that serve as the main sites of viral RNA synthesis. The origin of these membrane organelles is incompletely understood. Because the specific host pathways required for SARS-CoV-2 replication organelle formation are not defined, we asked whether SARS-CoV-2 is susceptible to modulators of lipid metabolism by assessing the sensitivity of the virus to VPS34 inhibitors of VPS34, a lipid kinase required for autophagy and endosomal trafficking; Triacsin C, an inhibitor of long chain fatty acyl CoA synthetase (ACSL) and Orlistat, an inhibitor of fatty acid synthase (FASN). Our preliminary data indicate that inhibitors of VPS34 potently inhibited SARS-CoV-2 replication, whereas an FDA- approved inhibitor of a different class of PI3K had minimal effect on replication. Targeting FASN and ACSL also impairs SARS-CoV-2 replication. These data suggest that VPS34, ACSL and FASN play important roles in replication center formation and virus growth and suggest these enzymes as therapeutic targets. We will test the hypothesis that VPS34, ACSL and FASN are critical for SARS-Cov-2 infection by evaluating additional small molecule inhibitors of these enzymes and by measuring SARS-CoV-2 replication in genetic knockdowns or knockouts of these host enzymes. We will define mechanisms of inhibition and test the hypothesis that generation of membrane-associated viral replication centers will be disrupted. Finally, we will assess the in vivo efficacy of VSP34 inhibitor PIK-III and systemically administered Orlistat in SARS-coV-2- infected hamsters to evaluate the therapeutic potential of inhibitors of lipid metabolism.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "7057", "attributes": { "award_id": "3U42OD011123-16S1", "title": "WaNPRC Macaca nemestrina SPF Breeding Colony", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "NIH Office of the Director" ], "program_reference_codes": [], "program_officials": [ { "id": 6567, "first_name": "MATTHEW ERIN", "last_name": "Arnegard", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2002-09-30", "end_date": "2024-05-31", "award_amount": 571856, "principal_investigator": { "id": 22854, "first_name": "CHARLOTTE", "last_name": "HOTCHKISS", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 159, "ror": "https://ror.org/00cvxb145", "name": "University of Washington", "address": "", "city": "", "state": "WA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 22855, "first_name": "Sally", "last_name": "Thompson-Iritani", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 159, "ror": "https://ror.org/00cvxb145", "name": "University of Washington", "address": "", "city": "", "state": "WA", "zip": "", "country": "United States", "approved": true }, "abstract": "Summary: The goal of this project is to maintain and enhance the specific pathogen free (SPF) pigtail macaque (M. nemestrina) breeding colony at the Washington National Primate Research Center (WaNPRC). This colony is the only major domestic breeding colony of M. nemestrina and the primary source of this important animal model for AIDS studies and other types of biomedical research in the United States. M. nemestrina have unique immunological, genetic, behavioral, anatomical, and physiological characteristics that make them an essential model in a number of areas of research related to HIV/AIDS. Specific pathogens (SIV, SRV, STLV-1, McHV-1) are a threat to animal or human health, or interfere with research and must be excluded to optimize nonhuman primate research models. In this proposal we discuss how we will maintain the WaNPRC SPF M. nemestrina breeding colony to provide animals of the highest quality to meet research needs. The SPF colony is housed at two locations, the Arizona Breeding Colony (ABC) which is an integral part of the WaNPRC, and at the New Iberia Research Center (NIRC). Having animals at two sites raises some challenges, but provides for contingencies in case of adverse events, and we have established lines of communication to ensure consistency. At both sites we will use innovative bioinformatics tools to increase cost effectiveness by maximizing production per animal. In addition, in our Seattle Infant Primate Research Laboratory (IPRL) we will initiate breeding for the production of expanded SPF M. nemestrina, which will be free of simian foamy virus (SFV), cytomegalovirus (MnCMV), rhadinovirus (MnRV), and simian varicella (SVV). Viral exclusion testing for all present and future excluded viruses will be performed by the Primate Diagnostic Services Laboratory (PDSL) through the virology core. We will use state-of-the-art genomics to characterize the animals, focusing on expressed alleles in the MHC region through the MHC Genetic Typing Core.", "keywords": [ "AIDS/HIV problem", "Acquired Immunodeficiency Syndrome", "Adverse event", "Alleles", "Anatomy", "Animal Genetics", "Animal Model", "Animals", "Area", "Arizona", "Behavioral", "Biomedical Research", "Breeding", "Characteristics", "Chickenpox", "Communication", "Communities", "Complex", "Cytomegalovirus", "Diagnostic Services", "Ensure", "Epithelial", "Epithelium", "Exclusion", "Exhibits", "Exposure to", "Faculty", "Future", "Genetic", "Genomics", "Goals", "Grant", "Guidelines", "Health", "Human", "Immune response", "Immunologics", "Infant", "Infection", "Infrastructure", "Laboratories", "Laboratory Research", "Location", "Macaca", "Macaca mulatta", "Macaca nemestrina", "Maintenance", "Mission", "Modeling", "Pathogenicity", "Physiological", "Primates", "Production", "Productivity", "Research", "Research Personnel", "Resources", "Rhadinovirus", "Risk", "SIV", "Sales", "Simian Foamy Virus", "Simian T-lymphotropic virus 1", "Site", "Source", "Subfamily lentivirinae", "Testing", "United States", "United States National Institutes of Health", "Vagina", "Viral", "Virus", "Washington", "animal breeding", "animal care", "base", "bioinformatics tool", "cost", "cost effectiveness", "germ free condition", "human disease", "human model", "improved", "innovation", "keratinization", "microbicide", "microorganism", "nonhuman primate", "pathogen", "pre-exposure prophylaxis", "vaginal microbiome", "virology" ], "approved": true } }, { "type": "Grant", "id": "5185", "attributes": { "award_id": "0938713", "title": "Washington ACS Meeting: Washington, DC; August 16-19, 2009", "funder": { "id": 3, "ror": "https://ror.org/021nxhr62", "name": "National Science Foundation", "approved": true }, "funder_divisions": [ "Unknown", "BIOMATERIALS PROGRAM" ], "program_reference_codes": [], "program_officials": [], "start_date": "2009-08-15", "end_date": "2010-07-31", "award_amount": 3500, "principal_investigator": { "id": 18389, "first_name": "Ting", "last_name": "Xu", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 176, "ror": "", "name": "University of California-Berkeley", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 176, "ror": "", "name": "University of California-Berkeley", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "ID: MPS/DMR/BMAT(7623) 0938713 PI: Xu, Ting ORG: California-Berkeley \n\nTitle: Washington ACS Meeting\n\nINTELLECTUAL MERIT: This proposal seeks support for travel awards for graduate students, post-docs, and underrepresented faculty to attend the symposium on ?Hybrid Soft Materials of Natural and Synthetic Polymers? at the Fall ACS national meeting in Washington, D.C., August, 16-19, 2009 in the Division of Polymeric Materials: Science and Engineering. The organizers aim to capture recent developments and present research in both well-developed stages and in new directions. The proposed symposium is divided into four specific focus areas: (1) Peptide-directed self-assembly, (2) Amphiphilic peptides, conjugates and assemblies, (3) Hybrid responsive biomaterials, (4) Hierarchical assemblies toward biomaterials. The threefold objectives of the symposium are: (1) to highlight recent advances in the design, synthesis, phase behavior and application of hybrid soft materials combining polymers and natural building blocks, (2) to provide a platform for the polymer chemist, polymer physicist, material scientist and bioengineer to establish connections and exchange ideas, (3) to facilitate opportunities for minority and junior faculty, postdoctoral fellows, and graduate students to present their most recent research results and extend their horizon and knowledge base of hybrid materials. This symposium will provide opportunities for both leaders and young investigators working in these focus areas to share their recent advances, ideas, challenges, and solutions with the expectation that approaches being developed in one area can directly impact and facilitate advances in the others. In addition, the integration of polymer scientists, biophysicists and engineers, who may approach material design in different manners, may facilitate more rapid advancement of these technologies. Finally, the format of the symposium is intended to facilitate discussion among all scientists in attendance.\n\nBROADER IMPACTS: Because the symposium is under the auspices of the ACS Division of Polymer Materials Science and Engineering (PMSE), every oral presentation will be accompanied by a two page abstract in PMSE Preprints. These abstracts contain pertinent references and significantly support the impact of the oral presentation. Younger scientists and those from underrepresented groups will benefit from the opportunity not only to meet one another but to hear from and meet international leaders in the field. The symposium has a strong interdisciplinary character and will stimulate discussions among participants with a variety of scientific backgrounds.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "9396", "attributes": { "award_id": "3U01HL152401-02S2", "title": "Washington Entrepreneurial Research Evaluation and Commercialization Hub", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "NIH Office of the Director" ], "program_reference_codes": [], "program_officials": [ { "id": 24937, "first_name": "KATHLEEN T", "last_name": "ROUSCHE", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2020-12-21", "end_date": "2022-11-30", "award_amount": 412300, "principal_investigator": { "id": 25133, "first_name": "RODNEY J Y", "last_name": "HO", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 159, "ror": "https://ror.org/00cvxb145", "name": "University of Washington", "address": "", "city": "", "state": "WA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 159, "ror": "https://ror.org/00cvxb145", "name": "University of Washington", "address": "", "city": "", "state": "WA", "zip": "", "country": "United States", "approved": true }, "abstract": "The overarching goal of the partnership between NIH and the University of Washington (UW) Entrepreneurial Center for Research Evaluation and Commercialization Hub (referred to as WE-REACH) is to facilitate and accelerate the transformation of health research innovations into products. This NIH funded WE-REACH Center is a National Center of REACH in the Northwest region. Two key objectives of the Center are to (1) assist investigators with innovative technologies to establish proof-of-product concept definition (2) facilitating the formation of spinout companies on track to a self-sustaining structure. With well-established expertise, know-how and infrastructure to assist the Research and Development of the following two Covid-19 technical- ready Covid-19 research and develop projects intended to verify proof-of-product concepts with working prototype. (1) Aptamer-based highly sensitive biosensors for salivary COVID-19 antigen detection (Pun) (2) Broad-spectrum detection of VOC and non-VOC biomarkers from patient exhalant using biomimetic multiplexed eNose biosensor for COVID-19 diagnosis (Saikaya) The two technically sound approaches employ by the point-of-care device candidates intend to detect viral antigen in saliva and exhalant biomarker signatures from infected subjects without having to send sample to a centralized facility or a long wait-time for results. WE-REACH will assist the investigators in developing milestone-driven, stage-gated, activity-based project planning and tracking to accelerate proof-of-product concept studies within 2-year of funding. The study results will provide measurable outcomes that are deemed sufficient for upscaling and appropriate for follow-on funding.", "keywords": [ "Biomimetics", "Biosensor", "COVID-19", "COVID-19 diagnosis", "COVID-19 test", "Clinical", "Communities", "Detection", "Development Plans", "Devices", "Evaluation Research", "Funding", "Goals", "Health", "Hospitals", "Individual", "Infrastructure", "Laboratories", "Measurable", "Outcome", "Reagent", "Research", "Research Personnel", "SARS-CoV-2 antigen", "Saliva", "Salivary", "Sampling", "Structure", "Testing", "Time", "United States National Institutes of Health", "Universities", "Viral Antigens", "Wait Time", "Washington", "antigen detection", "aptamer", "base", "biomarker signature", "commercialization", "innovation", "innovative technologies", "patient biomarkers", "point of care", "portability", "prevent", "prototype", "research and development", "sound" ], "approved": true } }, { "type": "Grant", "id": "6026", "attributes": { "award_id": "3UL1TR002345-05S1", "title": "WASHINGTON UNIVERSITY INSTITUTE OF CLINICAL AND TRANSLATIONAL SCIENCES", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Center for Advancing Translational Sciences (NCATS)" ], "program_reference_codes": [], "program_officials": [ { "id": 20574, "first_name": "Gallya", "last_name": "Gannot", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2017-06-19", "end_date": "2022-03-29", "award_amount": 67736, "principal_investigator": { "id": 20575, "first_name": "William G.", "last_name": "Powderly", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 827, "ror": "", "name": "WASHINGTON UNIVERSITY", "address": "", "city": "", "state": "MO", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 827, "ror": "", "name": "WASHINGTON UNIVERSITY", "address": "", "city": "", "state": "MO", "zip": "", "country": "United States", "approved": true }, "abstract": "The ACTIV public-private partnership has prioritized, designed, and harmonized five adaptive master protocols for ACTIV clinical trials, and selected numerous NIH-supported networks to launch these clinical trials to test prioritized therapeutic candidates. Master protocols allow coordinated and efficient evaluation of multiple investigational agents as they become available, but within the same clinical trial structure, across multiple study sites. Adaptive protocols swiftly weed out experimental drugs that do not demonstrate effectiveness and identify those that do. Adaptive master protocols reduce administrative burden and cost, provide a flexible framework to rapidly identify drugs that work, and rapidly move additional experimental agents into the trial. The ACTIV-1 master protocol is evaluating the safety and efficacy of at least three immune modulators (initially infliximab, abatacept and cencicrivoroc when given as an add-on therapy to standard of care, which currently includes remdesivir, The different treatments will be assessed with respect to illness severity, recovery speed, mortality and hospital resource utilization. Dr. Powderly is the Principal investigator for ACTIV-1 and the purpose of this supplement is to provide funding support for him and his Administrative Coordinator. In his role, he will participate in regular conference calls with ACTIV and NCATS leadership as well as leading weekly protocol team calls and regular calls with local PIs. He will review all safety events and other study end-points and present regular reports to the DSMB. He will also coordinate the reporting of the results and the writing of study manuscripts.", "keywords": [ "Clinical Sciences", "Clinical Trials", "Effectiveness", "Evaluation", "Event", "Funding", "Hospitals", "Immunomodulators", "Institutes", "Investigation", "Leadership", "Manuscripts", "Pharmaceutical Preparations", "Powder dose form", "Principal Investigator", "Protocols documentation", "Recovery", "Reporting", "Resources", "Role", "Safety", "Severity of illness", "Site", "Speed", "Structure", "Testing", "Translational Research", "United States National Institutes of Health", "Universities", "Washington", "Work", "Writing", "cost", "design", "flexibility", "infliximab", "mortality", "public-private partnership", "remdesivir", "standard of care", "support network", "symposium", "therapeutic candidate" ], "approved": true } }, { "type": "Grant", "id": "6765", "attributes": { "award_id": "4U01DA053976-02", "title": "Wastewater Analysis of SARS CoV-2 in Tribal Communities", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "NIH Office of the Director" ], "program_reference_codes": [], "program_officials": [ { "id": 22394, "first_name": "Tamara", "last_name": "Slipchenko", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2021-01-01", "end_date": "2023-05-31", "award_amount": 1305515, "principal_investigator": { "id": 4742, "first_name": "Otakuye", "last_name": "Conroy-Ben", "orcid": null, "emails": "[email protected]", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 147, "ror": "https://ror.org/03efmqc40", "name": "Arizona State University", "address": "", "city": "", "state": "AZ", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 22571, "first_name": "ROLF U", "last_name": "HALDEN", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 912, "ror": "", "name": "ARIZONA STATE UNIVERSITY-TEMPE CAMPUS", "address": "", "city": "", "state": "AZ", "zip": "", "country": "United States", "approved": true } ] }, { "id": 22572, "first_name": "Kerry", "last_name": "Hamilton", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 912, "ror": "", "name": "ARIZONA STATE UNIVERSITY-TEMPE CAMPUS", "address": "", "city": "", "state": "AZ", "zip": "", "country": "United States", "approved": true }, "abstract": "The rapid onset of the COVID-19 pandemic left many across the world unprepared to test, treat, and plan for coronavirus morbidity and mortality. This was true for Tribal nations, whose sovereign status enabled swift and preventative measures such as lock-downs and border closures, yet whose culture contributed to additional unique risk factors. Among those are testing disparities, underlying health factors, and community infrastructure. However, clinical testing doesn’t capture the extent of positive cases, and without the collective efforts of this project, Tribes will likely not be included in wastewater-based epidemiology (WBE) analysis, which has garnered wide-spread interest due to its ability to generate data in advance of community infectivity. In this project, we will show that WBE is a non-invasive, culturally appropriate biomonitoring strategy that can be adopted and implemented by Tribal communities to empower them with a practical, yet technologically advanced health surveillance tool. Building upon a rigorous methodology of Tribal consultation and community-based participatory research, assessment of wastewater and community infrastructure, and training of Tribal wastewater operators and health administrators on WBE, we will form the WBE Tribal Coordination Center. Tribes will be recruited through the InterTribal Council of Arizona’s National Tribal Water and Wastewater Operator Training Program network. We will measure coronavirus in wastewater across U.S. reservations using established RT-qPCR techniques and a novel protein quantification method, and we will sequence viral RNA extracts to assess SARS- CoV-2 variants in Tribal communities. Risk factors contributing to elevated COVID-19 in Tribal communities will be quantified with integration of geospatial analysis. Frameworks for risks from numerous environmentally- transmitted pathogens have been developed by our team, setting a foundation to incorporate variability and uncertainty for Tribal settings with qualitative information from Tribes in order to appropriately scope our modeling efforts. Simulation results will help to target resources efficiently for monitoring and public health interventions by identifying specific sampling locations where it is most likely to detect SARS-CoV-2 given other community and scientific constraints. Information from the RADx Data Coordination Center will be used to the fullest extent to compare Tribal communities with their non-Tribal counterparts. Through the coronavirus pandemic and beyond, Tribes will be better informed of their ability to use WBE to measure community health, thereby protecting community health and building capacity for future applications and research translation.", "keywords": [ "2019-nCoV", "Address", "Administrator", "Adopted", "American Indians", "Area", "Arizona", "Biological Assay", "Biological Monitoring", "COVID-19", "COVID-19 detection", "COVID-19 pandemic", "COVID-19 surveillance", "Case Study", "Cities", "Clinical Data", "Collection", "Communities", "Community Health", "Consultations", "Coronavirus", "Coronavirus Infections", "Custom", "Data", "Data Coordinating Center", "Databases", "Detection", "Distant", "Engineering", "Epidemiologic Monitoring", "Foundations", "Funding", "Future", "Genome", "Geography", "Health", "Health Priorities", "Health Status", "Healthcare", "High School Student", "Human", "Individual", "Information Systems", "Infrastructure", "Intervention", "Leadership", "Left", "Location", "Measures", "Methodology", "Methods", "Modeling", "Monitor", "Morbidity - disease rate", "Municipalities", "Native Americans", "North America", "Ownership", "Population", "Preventive measure", "Process", "Protein Analysis", "Proteins", "RADx", "RNA", "Registries", "Research", "Reservations", "Resources", "Risk", "Risk Factors", "Risk Management", "SARS-CoV-2 variant", "Sampling", "Sanitation", "Sentinel", "Sequence Analysis", "Services", "System", "Techniques", "Technology", "Testing", "Time", "Time trend", "Training", "Training Programs", "Translational Research", "Tribes", "Uncertainty", "United States", "United States Indian Health Service", "Universities", "Water", "Work", "community based participatory research", "community building", "cost", "cost effective", "data streams", "design", "disorder prevention", "genetic variant", "ground water", "health assessment", "improved", "interest", "intertribal", "metagenomic sequencing", "mortality", "novel", "novel coronavirus", "operation", "pandemic disease", "pathogen", "programs", "public health intervention", "recruit", "remote sensing", "research clinical testing", "simulation", "tool", "transcriptome sequencing", "trend", "tribal Nation", "tribal community", "tribal health", "tribal lands", "viral RNA", "wastewater epidemiology", "wastewater monitoring", "wastewater samples" ], "approved": true } }, { "type": "Grant", "id": "8015", "attributes": { "award_id": "1U01DA053976-01", "title": "Wastewater Analysis of SARS CoV-2 in Tribal Communities", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "NIH Office of the Director" ], "program_reference_codes": [], "program_officials": [ { "id": 22394, "first_name": "Tamara", "last_name": "Slipchenko", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2021-01-01", "end_date": "2023-05-31", "award_amount": 1494765, "principal_investigator": { "id": 4742, "first_name": "Otakuye", "last_name": "Conroy-Ben", "orcid": null, "emails": "[email protected]", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 147, "ror": "https://ror.org/03efmqc40", "name": "Arizona State University", "address": "", "city": "", "state": "AZ", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 22571, "first_name": "ROLF U", "last_name": "HALDEN", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 912, "ror": "", "name": "ARIZONA STATE UNIVERSITY-TEMPE CAMPUS", "address": "", "city": "", "state": "AZ", "zip": "", "country": "United States", "approved": true } ] }, { "id": 22572, "first_name": "Kerry", "last_name": "Hamilton", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 912, "ror": "", "name": "ARIZONA STATE UNIVERSITY-TEMPE CAMPUS", "address": "", "city": "", "state": "AZ", "zip": "", "country": "United States", "approved": true }, "abstract": "The rapid onset of the COVID-19 pandemic left many across the world unprepared to test, treat, and plan for coronavirus morbidity and mortality. This was true for Tribal nations, whose sovereign status enabled swift and preventative measures such as lock-downs and border closures, yet whose culture contributed to additional unique risk factors. Among those are testing disparities, underlying health factors, and community infrastructure. However, clinical testing doesn’t capture the extent of positive cases, and without the collective efforts of this project, Tribes will likely not be included in wastewater-based epidemiology (WBE) analysis, which has garnered wide-spread interest due to its ability to generate data in advance of community infectivity. In this project, we will show that WBE is a non-invasive, culturally appropriate biomonitoring strategy that can be adopted and implemented by Tribal communities to empower them with a practical, yet technologically advanced health surveillance tool. Building upon a rigorous methodology of Tribal consultation and community-based participatory research, assessment of wastewater and community infrastructure, and training of Tribal wastewater operators and health administrators on WBE, we will form the WBE Tribal Coordination Center. Tribes will be recruited through the InterTribal Council of Arizona’s National Tribal Water and Wastewater Operator Training Program network. We will measure coronavirus in wastewater across U.S. reservations using established RT-qPCR techniques and a novel protein quantification method, and we will sequence viral RNA extracts to assess SARS- CoV-2 variants in Tribal communities. Risk factors contributing to elevated COVID-19 in Tribal communities will be quantified with integration of geospatial analysis. Frameworks for risks from numerous environmentally- transmitted pathogens have been developed by our team, setting a foundation to incorporate variability and uncertainty for Tribal settings with qualitative information from Tribes in order to appropriately scope our modeling efforts. Simulation results will help to target resources efficiently for monitoring and public health interventions by identifying specific sampling locations where it is most likely to detect SARS-CoV-2 given other community and scientific constraints. Information from the RADx Data Coordination Center will be used to the fullest extent to compare Tribal communities with their non-Tribal counterparts. Through the coronavirus pandemic and beyond, Tribes will be better informed of their ability to use WBE to measure community health, thereby protecting community health and building capacity for future applications and research translation.", "keywords": [ "2019-nCoV", "Address", "Administrator", "Adopted", "American Indians", "Area", "Arizona", "Biological Assay", "Biological Monitoring", "COVID-19", "COVID-19 detection", "COVID-19 pandemic", "COVID-19 surveillance", "Case Study", "Cities", "Clinical Data", "Collection", "Communities", "Community Health", "Consultations", "Coronavirus", "Coronavirus Infections", "Custom", "Data", "Data Coordinating Center", "Databases", "Detection", "Distant", "Engineering", "Epidemiologic Monitoring", "Foundations", "Funding", "Future", "Genome", "Geography", "Health", "Health Priorities", "Health Status", "Healthcare", "High School Student", "Human", "Individual", "Information Systems", "Infrastructure", "Intervention", "Leadership", "Left", "Location", "Measures", "Methodology", "Methods", "Modeling", "Monitor", "Morbidity - disease rate", "Municipalities", "Native Americans", "North America", "Ownership", "Population", "Preventive measure", "Process", "Protein Analysis", "Proteins", "RADx", "RNA", "Registries", "Research", "Reservations", "Resources", "Risk", "Risk Factors", "Risk Management", "SARS-CoV-2 variant", "Sampling", "Sanitation", "Sentinel", "Sequence Analysis", "Services", "System", "Techniques", "Technology", "Testing", "Time", "Time trend", "Training", "Training Programs", "Translational Research", "Tribes", "Uncertainty", "United States", "United States Indian Health Service", "Universities", "Water", "Work", "community based participatory research", "community building", "cost", "cost effective", "data streams", "design", "disorder prevention", "genetic variant", "ground water", "health assessment", "improved", "interest", "intertribal", "metagenomic sequencing", "mortality", "novel", "novel coronavirus", "operation", "pandemic disease", "pathogen", "programs", "public health intervention", "recruit", "remote sensing", "research clinical testing", "simulation", "tool", "transcriptome sequencing", "trend", "tribal Nation", "tribal community", "tribal health", "tribal lands", "viral RNA", "wastewater epidemiology", "wastewater monitoring", "wastewater samples" ], "approved": true } }, { "type": "Grant", "id": "8008", "attributes": { "award_id": "1U01DA053903-01", "title": "Wastewater Assessment for Coronavirus in Kentucky: Implementing Enhanced Surveillance Technology", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "NIH Office of the Director" ], "program_reference_codes": [], "program_officials": [ { "id": 22394, "first_name": "Tamara", "last_name": "Slipchenko", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2021-01-01", "end_date": "2023-05-31", "award_amount": 1834258, "principal_investigator": { "id": 22395, "first_name": "Scott M", "last_name": "Berry", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1162, "ror": "https://ror.org/02k3smh20", "name": "University of Kentucky", "address": "", "city": "", "state": "KY", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1162, "ror": "https://ror.org/02k3smh20", "name": "University of Kentucky", "address": "", "city": "", "state": "KY", "zip": "", "country": "United States", "approved": true }, "abstract": "Wastewater Assessment for Coronavirus in Kentucky – Implementing Enhanced Surveillance Technology Surveillance for SARS-CoV-2 is hindered by the availability of testing, particularly in remote and rural areas. Screening of wastewater for SARS-CoV-2 viral biomarkers offers a viable alternative to individual testing and it can identify communities and facilities that are at risk of becoming hotspots.Wastewater surveillance overcomes several limitations of clinical surveillance, such as the need for robust healthcare and laboratory infrastructure and the lack of representative and comprehensive testing within communities. Conventional wastewater surveillance takes samples from sewer systems or wastewater treatment facilities and uses a series of extraction steps prior to advanced PCR technology to quantitate the viral biomarker (RNA). This approach is time and resource-intensive, which limits its wide-scale application. Developing next generation technology to simplify wastewater RNA extraction and quantitation will make it feasible to use more broadly at facilities and in rural communities. The limited clinical testing for COVID-19 in rural Southeastern Kentucky hampers disease surveillance and prevents informed public action to mitigate and contain the spread of disease. Wastewater testing for SARS-CoV- 2 in these communities using field-friendly technology will provide important information to local authorities and citizens about the spread and trend of SARS-CoV-2 infection in their communities. Our project will accomplish two aims: 1) Develop next generation wastewater assessment technology and 2) Implement and evaluate the next generation wastewater assay. For Aim 1 we adapt technology invented by our team termed exclusion-based sample preparation (ESP) to simplify and improve RNA extraction from wastewater. We will pair ESP with loop-mediated isothermal amplification (LAMP) technology for RNA detection to create a sensitive, robust, and field-friendly platform for testing wastewater for SARS- CoV-2 RNA. We will compare the next generation assay with established techniques on metrics of sensitivity, specificity, and usability (e.g., assay time, number of assay steps). For Aim 2 we will first validate the next generation assay in the field at congregate living facilities in a side-by-side comparison with conventional wastewater surveillance. Next, building on existing relationships in Appalachian Kentucky, we will recruit and train a purposive group of wastewater treatment plant operators, watershed watch citizen scientists, and school science teachers to test wastewater in their communities and schools using the field-friendly next generation wastewater assay. Field results will be validated in the lab. A robust mixed methods evaluation using the RE-AIM framework will assess community perceptions of feasibility, acceptability, and utility of wastewater surveillance for SARS-CoV-2 and identify community measures taken in response to test results.", "keywords": [ "2019-nCoV", "Appalachian Region", "Biological Assay", "Biological Markers", "COVID-19 assay", "COVID-19 detection", "COVID-19 outbreak", "COVID-19 surveillance", "COVID-19 testing", "Characteristics", "Cities", "Clinical", "Cold Chains", "Communities", "Coronavirus", "Detection", "Disease", "Disease Surveillance", "Evaluation", "Exclusion", "Feces", "Goals", "Healthcare", "Heating", "Hour", "Individual", "Infection", "Infection prevention", "Infrastructure", "Kentucky", "Laboratories", "Measures", "Mediating", "Methods", "Molecular Biology Techniques", "Monitor", "Nursing Homes", "Perception", "Performance", "Persons", "Plants", "Population", "Preparation", "Prevention Measures", "Prisons", "RADx Radical", "RNA", "RNA Degradation", "Reach Effectiveness Adoption Implementation and Maintenance", "Resources", "Reverse Transcriptase Polymerase Chain Reaction", "Ribonucleases", "Risk", "Rural", "Rural Appalachia", "Rural Community", "Rural Population", "SARS-CoV-2 infection", "Sampling", "Schools", "Sensitivity and Specificity", "Series", "Side", "Signal Transduction", "Surveillance Methods", "Syncope", "System", "Techniques", "Technology", "Technology Assessment", "Test Result", "Testing", "Time", "Training", "United States", "United States National Institutes of Health", "Universities", "Viral", "Vulnerable Populations", "authority", "base", "citizen science", "community based participatory research", "experience", "field study", "high risk", "improved", "innovation", "isothermal amplification", "new technology", "next generation", "point of care", "prevent", "recruit", "research clinical testing", "response", "rural area", "rural setting", "sample collection", "science teacher", "trend", "usability", "wastewater samples", "wastewater sampling", "wastewater screening", "wastewater surveillance", "wastewater testing" ], "approved": true } }, { "type": "Grant", "id": "6687", "attributes": { "award_id": "4U01DA053903-02", "title": "Wastewater Assessment for Coronavirus in Kentucky: Implementing Enhanced Surveillance Technology", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "NIH Office of the Director" ], "program_reference_codes": [], "program_officials": [ { "id": 22394, "first_name": "Tamara", "last_name": "Slipchenko", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2021-01-01", "end_date": "2023-05-31", "award_amount": 1546299, "principal_investigator": { "id": 22395, "first_name": "Scott M", "last_name": "Berry", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1162, "ror": "https://ror.org/02k3smh20", "name": "University of Kentucky", "address": "", "city": "", "state": "KY", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1162, "ror": "https://ror.org/02k3smh20", "name": "University of Kentucky", "address": "", "city": "", "state": "KY", "zip": "", "country": "United States", "approved": true }, "abstract": "Wastewater Assessment for Coronavirus in Kentucky – Implementing Enhanced Surveillance Technology Surveillance for SARS-CoV-2 is hindered by the availability of testing, particularly in remote and rural areas. Screening of wastewater for SARS-CoV-2 viral biomarkers offers a viable alternative to individual testing and it can identify communities and facilities that are at risk of becoming hotspots.Wastewater surveillance overcomes several limitations of clinical surveillance, such as the need for robust healthcare and laboratory infrastructure and the lack of representative and comprehensive testing within communities. Conventional wastewater surveillance takes samples from sewer systems or wastewater treatment facilities and uses a series of extraction steps prior to advanced PCR technology to quantitate the viral biomarker (RNA). This approach is time and resource-intensive, which limits its wide-scale application. Developing next generation technology to simplify wastewater RNA extraction and quantitation will make it feasible to use more broadly at facilities and in rural communities. The limited clinical testing for COVID-19 in rural Southeastern Kentucky hampers disease surveillance and prevents informed public action to mitigate and contain the spread of disease. Wastewater testing for SARS-CoV- 2 in these communities using field-friendly technology will provide important information to local authorities and citizens about the spread and trend of SARS-CoV-2 infection in their communities. Our project will accomplish two aims: 1) Develop next generation wastewater assessment technology and 2) Implement and evaluate the next generation wastewater assay. For Aim 1 we adapt technology invented by our team termed exclusion-based sample preparation (ESP) to simplify and improve RNA extraction from wastewater. We will pair ESP with loop-mediated isothermal amplification (LAMP) technology for RNA detection to create a sensitive, robust, and field-friendly platform for testing wastewater for SARS- CoV-2 RNA. We will compare the next generation assay with established techniques on metrics of sensitivity, specificity, and usability (e.g., assay time, number of assay steps). For Aim 2 we will first validate the next generation assay in the field at congregate living facilities in a side-by-side comparison with conventional wastewater surveillance. Next, building on existing relationships in Appalachian Kentucky, we will recruit and train a purposive group of wastewater treatment plant operators, watershed watch citizen scientists, and school science teachers to test wastewater in their communities and schools using the field-friendly next generation wastewater assay. Field results will be validated in the lab. A robust mixed methods evaluation using the RE-AIM framework will assess community perceptions of feasibility, acceptability, and utility of wastewater surveillance for SARS-CoV-2 and identify community measures taken in response to test results.", "keywords": [ "2019-nCoV", "Appalachian Region", "Biological Assay", "Biological Markers", "COVID-19 assay", "COVID-19 detection", "COVID-19 outbreak", "COVID-19 surveillance", "COVID-19 testing", "Characteristics", "Cities", "Clinical", "Cold Chains", "Communities", "Coronavirus", "Detection", "Disease", "Disease Surveillance", "Evaluation", "Exclusion", "Feces", "Goals", "Healthcare", "Heating", "Hour", "Individual", "Infection", "Infection prevention", "Infrastructure", "Kentucky", "Laboratories", "Measures", "Mediating", "Methods", "Molecular Biology Techniques", "Monitor", "Nursing Homes", "Perception", "Performance", "Persons", "Plants", "Population", "Preparation", "Prevention Measures", "Prisons", "RADx Radical", "RNA", "RNA Degradation", "Reach Effectiveness Adoption Implementation and Maintenance", "Resources", "Reverse Transcriptase Polymerase Chain Reaction", "Ribonucleases", "Risk", "Rural", "Rural Appalachia", "Rural Community", "Rural Population", "SARS-CoV-2 infection", "Sampling", "Schools", "Sensitivity and Specificity", "Series", "Side", "Signal Transduction", "Surveillance Methods", "Syncope", "System", "Techniques", "Technology", "Technology Assessment", "Test Result", "Testing", "Time", "Training", "United States", "United States National Institutes of Health", "Universities", "Viral", "Vulnerable Populations", "authority", "base", "citizen science", "community based participatory research", "experience", "field study", "high risk", "improved", "innovation", "isothermal amplification", "new technology", "next generation", "point of care", "prevent", "recruit", "research clinical testing", "response", "rural area", "rural setting", "sample collection", "science teacher", "trend", "usability", "wastewater samples", "wastewater sampling", "wastewater screening", "wastewater surveillance", "wastewater testing" ], "approved": true } } ], "meta": { "pagination": { "page": 1382, "pages": 1397, "count": 13961 } } }